Tamas Sohajda’s Post

A recent article, published in Pharmaceutical Research, highlighted the problems associated with visible and sub-visible particle formation in protein formulations due to hydrolytic degradation of polysorbate 20. Learn more https://ow.ly/UkuX30synCF Find out what we have been doing to help reduce the risk of visible and sub-visible particle formation. Read more here ow.ly/GVPP30synBE

🤔 Would you like to learn more about the role of Raman & SEM-EDS analysis in the pharmaceutical industry? Watch our on-demand webinar now, where you'll learn this PLUS more 👉 https://okt.to/FLIUYh #RamanMicroscopy #EnergyDispersiveSpectroscopy #SEMEDS #SEM #ScanningElectronMicroscopes #Raman #PharmaceuticalResearch

A recent article, published in Pharmaceutical Research, highlighted the problems associated with visible and sub-visible particle formation in protein formulations due to hydrolytic degradation of polysorbate 20. Learn more https://ow.ly/oUne30syroU Find out what we have been doing to help reduce the risk of visible and sub-visible particle formation. Read more here ow.ly/GVPP30synBE

A recent article, published in Pharmaceutical Research, highlighted the problems associated with visible and sub-visible particle formation in protein formulations due to hydrolytic degradation of polysorbate 20. Learn more https://ow.ly/Iaqm30syvCR Find out what we have been doing to help reduce the risk of visible and sub-visible particle formation. Read more here ow.ly/GVPP30synBE

A high percentage of pharmaceutical targets are ‘undruggable’ by small molecules. To address this issue, researchers have recently turned to Proteolysis Targeting Chimeras (PROTACs®). Join our next webinar on 12th December, 'Streamlining the design of PROTACs® and PROTAC linkers', where we'll explore PROTACs and demonstrate how software solutions Spark™ and Flare™ can help overcome some of these challenges and streamline the design of PROTACs and PROTAC linkers. Register here: https://lnkd.in/e_AKHZmU #DMTA #CADD #smallmolecule #drugdiscovery #drugdesign #PROTACS

A recent article, published in Pharmaceutical Research, highlighted the problems associated with visible and sub-visible particle formation in protein formulations due to hydrolytic degradation of polysorbate 20. Learn more https://ow.ly/OP6F30syvL6 Find out what we have been doing to help reduce the risk of visible and sub-visible particle formation. Read more here ow.ly/GVPP30synBE

A recent article, published in Pharmaceutical Research, highlighted the problems associated with visible and sub-visible particle formation in protein formulations due to hydrolytic degradation of polysorbate 20. Learn more https://ow.ly/MViZ30syprU Find out what we have been doing to help reduce the risk of visible and sub-visible particle formation. Read more here ow.ly/GVPP30synBE

Western blots are frequently included in pharmaceutical research papers. But as a common source of image integrity issues, publishing these figures with any duplications — even if they are unintentional — can undermine the integrity of the research, as well as potentially impacting future treatments. Read our article on why western blots are a key hurdle to overcome with pharmaceutical research integrity. https://bit.ly/450XDmL #ImageIntegrity #PharmaResearch  

What if there were a way to reduce risk and uncertainty in API development? Read more from my colleagues Simon Wagschal and Jen Schmidt on how automation and artificial intelligence are enabling more efficient small molecule drug development in this article with Pharmaceutical Technology. https://lnkd.in/g5drKc6Q

A recent article, published in Pharmaceutical Research, highlighted the problems associated with visible and sub-visible particle formation in protein formulations due to hydrolytic degradation of polysorbate 20. Learn more https://ow.ly/VUl630syETk Find out what we have been doing to help reduce the risk of visible and sub-visible particle formation. Read more here ow.ly/GVPP30synBE